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Porphyrias are a heterogeneous group of metabolic disorders that result from the altered activity of specific enzymes of the heme
biosynthetic pathway and are characterized by accumulation of pathway intermediates. Porphyria cutanea tarda (PCT) is the most
common porphyria and is due to deficient activity of uroporphyrinogen decarboxylase (UROD). Acute intermittent porphyria
(AIP) is the most common of the acute hepatic porphyrias, caused by decreased activity of hydroxymethylbilane synthase
(HMBS). An Argentinean man with a family history of PCT who carried the UROD variant c.10_11insA suffered severe ab-
dominal pain. Biochemical testing was consistent with AIP, and molecular analysis of HMBS revealed a de novo variant:
c.344 + 2_ + 5delTAAG. *is is one of the few cases of porphyria identified with both UROD and HMBS mutations and the first
confirmed case of porphyria with dual enzyme deficiencies in Argentina.
1. Introduction
Porphyria cutanea tarda (PCT), the most common type of
porphyria, is due to decreased hepatic activity of uropor-
phyrinogen decarboxylase (UROD; EC 4.1.1.37), the fifth
enzyme in the heme biosynthetic pathway [1]. Accumulation
of porphyrins causes skin fragility and blistering on sun-
exposed areas, often with hyperpigmentation and hyper-
trichosis. *ree clinically similar forms of PCT are sporadic
(S-PCT) or type I, OMIM 176090; familial (F-PCT) or type
II, OMIM 176100; and type III PCT. F-PCT is an autosomal
dominant disorder with low penetrance in which the UROD
activity is reduced in all tissues due to pathogenic variants.
F-PCTrepresents about 20–30% of PCTpatients, in whom a
UROD mutation predisposes to the development of the
disease. Most PCT patients have S-PCT, which is not as-
sociated with UROD variants [2–4]. Type III PCT is rare,
with familial occurrence in more than one family member in
the absence of UROD mutations [3].
Acute intermittent porphyria (AIP), OMIM 176000, is
the most common of the acute hepatic porphyrias in most
countries [5, 6]. It is an autosomal dominant disorder with
incomplete penetrance, caused by the deficient activity of
hydroxymethylbilane synthase (HMBS), also known as
porphobilinogen deaminase (PBGD EC 4.3.1.8). Acute ab-
dominal pain and various peripheral and central nervous
system manifestations are the most frequent symptoms,
which can be precipitated by diverse exogenous and en-
dogenous porphyrinogenic factors [2, 7]. Symptomatic as
well as most clinical asymptomatic patients with AIP excrete
increased levels of δ-aminolevulinic acid (ALA), porpho-
bilinogen (PBG), and porphyrins, which can be readily
measured in urine. Latent patients have normal ALA, PBG,
and porphyrin values, and their diagnosis is based mainly on
genetic analysis [6, 8].
2. Methods and Results
A 68-year-old male presented with skin fragility, scabs,
macules, and dark urine. He was diagnosed as having PCT
based on marked elevation in urinary porphyrins, with a
predominance of highly carboxylated porphyrins (Table 1).
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2 Case Reports in Genetics
Molecular testing detected a UROD pathogenic variant,
c.10_11insA, which is the most common one found in PCT
patients in Argentina [8]. It should be noted that the
symptoms in this man have developed for more than 30
years. A combined treatment with eight phlebotomies
(500ml/each) to diminish iron content and OH chloroquine
(100mg/twice a week) till remission of symptoms was
performed in this patient.
In 2015, one of his sons, who was the youngest of 5
siblings, presented at the age of 40 with severe abdominal
pain, vomiting, and fever but without cutaneous manifes-
tations. Biochemical tests by previously described methods
[9] were consistent with AIP (Table 2).
Molecular analysis revealed that he had inherited the
UROD variant c.10_11insA which was found previously in his
father and also harboured a deletion of four bases in intron 7
of HMBS (IVS7+ 2_+ 5delTAAG, c.344 + 2_+ 5delTAAG)
(Figure 1). *is deletion variant was first reported as causing
AIP in a patient in Russia [10] and has not been identified
previously in Argentina.*e patient’s parents, two sisters, and
one brother were studied (Figure 2).
Allele segregation analysis was carried out based on
single nucleotide polymorphisms (SNPs) previously studied
in AIP families in Argentina. Six intragenic SNPs were
found: five of them were identified previously in our pop-
ulation [11], and a novel SNP was found in intron 9
(g.5481C>T) which was inherited from his father, who was
of Italian origin (Figure 3).
Management of AIP attacks required treatment and
monitoring by the responsible doctor, at J. M. Ramos Mejia
Hospital, Attention Center for Porphyric Patients. Oral folic
acid (90mg) was administrated (30mg/8 h), vitamin B
complex (B1, B6 and B12) was consumed orally every 8 hours,
and carbohydrate loading (350 g) was the standard treatment
for an acute attack of porphyria, following a specific diet.
Some symptoms have been treated by propranolol (40mg/
12 h) and clonazepam (0.5mg/6 h). *e treatment also re-
quired the psychotherapeutic support. *e patient did not
work for 3 months till ALA, PBG, and porphyrins values were
stabilized. Six months later, the doses of folic acid and B
complex were reduced, a suitable diet wasmaintained, and the
patient was stable and without new attacks.
3. Discussion
Porphyrias are rare metabolic diseases often misdiagnosed
because they share symptoms which are common in many
other diseases. Attacks of the acute hepatic porphyrias are
Table 2: Biochemical analyses in the son.
Date Qualitative PBG test ALA, mg/24 h PBG, mg/24 h UTP, µg/24 h PPI (λ, 619 nm) HMBS, U/ml GR UTLC (%)
09.10.15 Positive 2316 3.07 Unusual pattern
04.11.15 11.3 38.7 1318 2.17 57.78
21.12.15 10.9 31.7 1131
23.03.16 4.7 13.4 1612
21.07.16 2.5 5.0 991
01.03.17 Positive 1.5 5.2 591
Normal value of HMBS: 73,3± 13,6.
(a) (b)
Figure 1: Electropherogram for (a) UROD and (b) HMBS sequences.
Case Reports in Genetics 3
triggered by a variety of endogenous and exogenous factors.
Early diagnosis is important for advising patients, especially
those with latent disease, to avoid such factors and to treat
symptoms that do occur promptly to elude severe clinical
consequences.
In this family, the father presented with skin lesions at the
age of 68 and was found to have biochemical changes typical
of PCT and carried c.10_11insA in UROD, which is the most
frequent variant associated with type II PCT in Argentina
[12]. He had 3 sons and 2 daughters, none of whom had
developed cutaneous manifestations. In 2015, one son de-
veloped severe abdominal pain, a symptom not attributable to
PCT. Biochemical finding was consistent with AIP. UROD
and HMBS were analysed, and the results showed the UROD
familial variant was inherited from his father, but the HMBS
variant was only found in this patient. *e same HMBS
mutation was previously reported as a novel variant associ-
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Figure 2: Pedigree of the studied Argentinean family with PCT (a) and AIP (b).
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Figure 3: Allele segregation analysis using intragenic SNPs in HMBS. SNP underlined indicates a novel SNP in Argentinean population.
Position of nucleotide change is numbered relative to the translation initiation codon in Exon 1 in genomic DNA sequence (GenBank
accession no. M95623, A in the ATG initiation codon for the housekeeping isoform is +1).
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We carried out genetic analysis in his family (one brother
did not consent to be studied). Only one of the analysed
siblings carried the familial UROD variant.
Allele segregation analysis based on SNPs, already de-
scribed in our population [14], indicated that the proband’s
HMBS variant was not found in either parent providing
evidence for a de novo mutation.
Porphyrias are infrequent diseases, but it is even more
rare to find mutations in different genes that may cause two
types of porphyria in one individual [13, 15–23]. In our
studied case, a UROD variant was inherited from one
parent, and the patient had typical findings of AIP due to a
de novo HMBS variant. In contrast to his father, he did not
develop features of PCT. Whether the inherited UROD
mutation contributed to the severity of AIP is uncertain,
although we found an unusual urinary pattern in this case.
Both UROD and HMBS mutations have already been in-
dividually reported. *is is the first instance in Argentina
where these variants were found together in the same
individual, being one of them a de novo mutation. It is
interesting to note that de novo mutations are very rare
events in porphyrias [24, 25].
4. Conclusions
A de novo variant (c.344 + 2_ + 5delTAAG) was identified
for the first time in Argentina. *is is the first report of a
patient with dual porphyria (AIP/PCT) in Argentina with
molecular confirmation.
It must be emphasized the importance of carrying out a
complete clinical, biochemical, and molecular study to apply
the specific treatment, which is critical in cases of coexis-
tence of a cutaneous porphyria with an acute porphyria since


















PCR: Polymerase chain reaction
PCT: Porphyria cutanea tarda




*e datasets used and/or analysed during the current study
are available from the corresponding author on reasonable
request.
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